Urgent/emergent percutaneous transvenous mitral commissurotomy

Percutaneous transvenous mitral commissurotomy versus surgical commissurotomy in the treatment of mitral stenosis

There is no doubt that percutaneous transvenous mitral commissurotomy (PTMC) in experienced centers is associated with a low risk of major complications and yields excellent immediate and long-term outcome. Although previous observational studies on both PTMC and surgical commissurotomy have indicated similar outcome between the two treatment strategies in terms of valve area improvement and risk of major complication (death, thromboembolism and significant resultant mitral regurgitation), it was not until recently that several prospective randomized trials comparing the two procedures and involving > 470 patients with favorable valve characteristics (pliable, noncalcified valve with mild subvalvular disease and no or mild mitral regurgitation), have confirmed that PTMC is indeed just as, if not more, effective as surgical commissurotomy. The late restenosis rate at up to 3-year follow-up appears comparable. Furthermore, PTMC has other additional benefits. It is nontraumatic, may be repeated without additional risk, and has been shown to be an extremely useful and efficacious palliative tool in those with end-stage mitral stenosis or with unfavorable valve anatomy who refuse surgery, and in certain subset of patients at high surgical risk because of medical comorbidities.

Emergencies in valve disease

PURPOSE OF REVIEW

This review will deal with strategies for emergency management of patients with valve disease, a situation that is now rare but remains a very challenging problem: valvular patients are often elderly with a high frequency of comorbidity; furthermore, there is a growing proportion of previously operated patients who present with further problems.

RECENT FINDINGS

The main treatment is valve replacement, however, the conservative surgical approach is developing, and, more recently, percutaneous interventional techniques have been introduced. Percutaneous mitral commissurotomy is an established treatment for mitral stenosis whereas transcatheter aortic valve implantation, which is presently at the evaluation phase, shows promise.

SUMMARY

The keys to success are establishing a rapid diagnosis based mainly on echocardiography followed by early intervention. Every effort should be made to avoid performing intervention in an emergency setting, as it is always of high risk. Strategies include better patient and physician education in order to decrease the incidence of endocarditis and prosthetic-related complications such as thromboembolism and considering earlier intervention when symptoms or objective signs of ventricular dysfunction are observed in patients with known valve disease.

Acquired Heart Disease in Pregnancy

The incidence of rheumatic heart disease in most industrialized countries is decreasing. Those women who have regurgitant lesions will commonly experience an improvement in symptoms, and therapy is required only in the most severe cases. Women with mild to moderate stenotic lesions can usually expect a good outcome to pregnancy, but women with severe stenotic lesions require close monitoring by both their obstetricians and their cardiologists, especially during the third trimester, labour and delivery, and the early postpartum period. This is the third in a series of five articles reviewing in detail the assessment and management of specific cardiac disorders in pregnancy.

Bedside percutaneous transseptal mitral commissurotomy under sole transthoracic echocardiographic guidance in a critically ill patient

Percutaneous transvenous mitral commissurotomy is an effective and safe alternative to surgical treatment, in selected patients of rheumatic mitral stenosis. It is usually performed under fluoroscopic guidance in the catheterization laboratory. We report the successful performance of emergency mitral commissurotomy by the Inoue balloon at bedside under sole transthoracic echocardiographic guidance in a critically ill patient.

Emergent balloon mitral valvotomy in patients presenting with cardiac arrest, cardiogenic shock or refractory pulmonary edema

OBJECTIVES

The present study was performed to determine the outcome of emergent balloon mitral valvotomy (BMV) in patients with cardiac arrest, pulmonary edema or cardiogenic shock.

BACKGROUND

In India, many patients with mitral stenosis present in critical condition. They have high mortality despite surgical relief. The role of BMV in such patients is ill-defined.

METHODS

Of 558 patients undergoing BMV between January 1993 and December 1994, 40 presented with cardiogenic shock, cardiac arrest or pulmonary edema refractory to medical treatment and underwent emergent BMV (group I). Elective BMV was performed in the remaining 518 patients (group II).

RESULTS

Age ([mean +/- SD] 40 +/- 13 vs. 31 +/- 9 years, p < 0.05), incidence of atrial fibrillation (35% vs. 11%, p < 0.05), pulmonary artery systolic pressure (PAsP) (64 +/- 14 vs. 51 +/- 12 mm Hg, p < 0.001) and mitral valve (MV) score (7.4 +/- 1.2 vs. 6.4 +/- 1, p < 0.001) were higher and MV area lower (0.74 +/- 0.17 vs. 0.86 +/- 0.14 cm2, p < 0.001) in group I patients. After emergent BMV in group I, mitral regurgitation occurred in 15%, and the mortality rate was 35%. Stepwise logistic regression analysis identified MV score > or =8 (p = 0.008), PAsP > or =65 mm Hg (p = 0.023) and cardiac output < or =3.151 liters/min (p = 0.001) as significant predictors of a fatal outcome. Follow-up of 1 to 16 months (median 8) was available in 20 of 26 survivors in group I, of whom 15 were asymptomatic. The gain in MV area and the decrease in transmitral gradient and PAsP obtained immediately after BMV persisted during the follow-up period.

CONCLUSIONS

Emergent BMV is feasible in critically ill patients. In-hospital survivors have excellent clinical and hemodynamic status at intermediate follow-up.

Percutaneous balloon mitral valvuloplasty

Percutaneous balloon mitral valvuloplasty, first performed by Inoue in 1982, was a rational progression from 4 decades of experience with the blunt surgical dilatation technique of closed mitral commissurotomy. As with surgical commissurotomy, balloon valvuloplasty relieves mitral stenosis by the splitting of fused commissures. A series of studies have shown that balloon valvuloplasty achieves excellent acute hemodynamic results in close to 90% of patients, with a typical 100% increase in mitral valve area. Over the past 15 years since Inoue's first patient, a number of other techniques have been introduced and largely discarded in favor of the original approach. Advances have occurred along the lines of improved noninvasive assessment of mitral valve disease, which have allowed better case selection and prediction of outcome. Follow-up series have shown sustained improvement, with modest rates of complications and restenosis. Comparative studies have shown that balloon valvuloplasty is as effective and safe as surgical commissurotomy, and is a cost-effective procedure of first choice in ideal patients.

Versatility of Inoue balloon catheter

Inoue rubber nylon single balloon catheter is being used worldwide for performing balloon mitral valvuloplasty (BMV). The popularity of Inoue balloon is attributed to its self-positioning configuration, size-adjustability, rapid inflation-deflation sequence and the ease of performance. We report its use in performing various non-mitral interventions. Its utility in treating patients with mitral stenosis and combined mitral and tricuspid stenosis is well established. Seventeen patients with valvular pulmonic stenosis (age 32+/-16 years; 11 males and 6 females) achieved significant reduction of peak systolic gradient (PSG) from 125+/-28 to 32+/-16 mmHg (P<0.005). Four patients with inferior vena-cava obstruction (age 20-48 years; 3 males and 1 female) derived symptomatic benefit following successful dilatation. Inoue balloon was used to create percutaneous pericardial window in four cases (age 43-68 years; 2 males and 2 females) of recurrent pericardial collection secondary to carcinoma lung/breast, thus alleviating the symptoms of tamponade. One patient each with coarctation of aorta (32 years, male), discrete subaortic membrane (16 years, female), and critical valvular aortic stenosis (13 years, male) derived immediate hemodynamic improvement with Inoue balloon dilatation. No major complications were encountered. We conclude that Inoue balloon can be used to successfully manage various stenotic lesions.

Pitfalls and tips in inoue balloon mitral commissurotomy

Balloon mitral commissurotomy is a safe and effective alternative therapeutic modality in selected patients with significant rheumatic mitral stenosis. Since its introduction in 1984, Inoue balloon mitral commissurotomy has gained wider acceptance over other balloon valvuloplasty techniques because it is technically less demanding and associated with fewer complications. Nevertheless, certain pitfalls which may make the procedure more difficult or create complications are sometimes encountered. In this article, we offer tips to facilitate a safe and expeditious execution of Inoue balloon mitral commissurotomy based on our experience with over 1,000 procedures.

Balloon mitral valvotomy: an autopsy study

The autopsy findings in 20 patients who died following percutaneous balloon mitral valvotomy are reported. The procedure was attempted in 508 patients. In 17 of the 20 patients, balloon mitral valvotomy was attempted as a salvage procedure. Ten patients died in the immediate post valvotomy period (within 24 h), seven died within a week and three between 1 to 3 months. In 13 patients, the balloon valvotomy successfully opened out one or both commissures. Interatrial septostomy defects created by the transeptal catheter could be identified in 19 of 20 heart specimens. The size of the defects ranged from small (5 mm) openings to large (15 mm) defects especially with double balloon. Marked mitral valvar thickening with nodular calcification was observed in 16 cases. Significant complications leading to mortality included cardiac tamponade (five cases) due to left ventricle apical perforation (3/5 cases). Mitral valve damage in the form of leaflet tears, chordal rupture and long splits in five cases resulted in significant mitral regurgitation. The leaflet tears resulted in detachment of part of the leaflet from the annulus. A late complication noted was infective endocarditis. Associated pulmonary tuberculosis, chronic obstructive pulmonary disease, respiratory infections and multivalvar diseases also contributed to mortality.

Percutaneous balloon mitral valvuloplasty by the Inoue technique: a multicenter study of 4832 patients in China

Between November 1985 and January 1994, 4832 patients with rheumatic mitral stenosis from 120 medical centers in China underwent PBMV by the Inoue technic. There were 1440 men and 3392 women with a mean age of 36.8 +/- 12.3 years. The procedure success rate was 99.30%. Major complications included death in 0.12%, > or = 3+/4+ mitral regurgitation in 1.41%, cardiac tamponade in 0.81%, and thromboembolism in 0.48%. After PBMV, the mean left atrial pressure decreased from 26.2 +/- 7.6 mm Hg to 11.4 +/- 6.1 mm Hg (p < 0.001); mean mitral diastolic gradient decreased from 18.3 +/- 5.1 mm Hg to 5.4 +/- 3.1 mm Hg (p < 0.001); pulmonary artery systolic pressure decreased from 51.2 +/- 14.8 mm Hg to 33.9 +/- 8.8 mm Hg (p < 0.001); cardiac output increased from 3.8 +/- 1.3 L/min to 4.8 +/- 1.2 L/min (p < 0.001); and mitral valve area expanded from 1.1 +/- 0.3 cm2 to 2.1 +/- 0.2 cm2 (p < 0.001). Functional status was NYHA class IV in 5.6%, class III in 38.8%, class II in 55.5%, and class I in 0.1% of patients before PBMV and improved to class I in 75.8%, class II in 23%, and class III in 1.2% after PBMV. The rate of restenosis was 5.2% over a follow-up period of 32.2 +/- 14.2 months in the entire group and 4.6% over a follow-up period of 5.1 +/- 1.0 years in Guangdong Cardiovascular Institute, where PBMV was begun in China.(ABSTRACT TRUNCATED AT 250 WORDS)

Controversies in balloon mitral valvuloplasty: the when (timing for intervention), what (choice of valve), and how (selection of technique)

Despite the established role of percutaneous balloon mitral valvuloplasty (BMV) in the treatment of mitral stenosis, major controversial issues in the realm of BMV persist. With increased operator experience, BMV has now been extended to include various controversial scenarios, such as mild mitral stenosis, adverse valve morphologies, and high-risk patients with concomitant anatomic distortions which are technically demanding. In skilled hands, however, BMV has yielded a favorable outcome in these settings. Furthermore, the debate on whether the Inoue or the double-balloon approach is superior continues. Studies to date have shown equal efficacy of the two BMV methods in terms of valve enlargement although the Inoue approach is clearly simpler to execute and may potentially be associated with a lower risk of creating severe mitral regurgitation. Last, because of the lack of consensus on optimal balloon sizing for BMV, perhaps the best method to adopt at this stage is one that is simple and safe to apply across a broad spectrum of valve anatomy.